Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORLESTRIN 28 1/50 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norethindrone: 8 hours; ethinyl estradiol: 12-15 hours; steady state achieved within 5-10 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol: primarily metabolized by CYP3A4 via hydroxylation, conjugated as glucuronides and sulfates. Norethindrone: reduced to dihydro- and tetrahydro-metabolites, conjugated, with minor CYP3A4 involvement.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Norethindrone: 40% renal, 60% fecal; ethinyl estradiol: 40% renal, 60% fecal.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethindrone: 80% bound to albumin and SHBG; ethinyl estradiol: 97% bound to albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethindrone: 2.5 L/kg; ethinyl estradiol: 4.5 L/kg; indicates extensive distribution into tissues.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Norethindrone: 100% oral; ethinyl estradiol: 45% oral due to first-pass metabolism.
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or renal failure.
No data available for fictional drug ALYACEN 777.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
No data available for fictional drug ALYACEN 777.
Not indicated for premenarchal females. For postmenarchal adolescents, same as adult dosing: one tablet orally once daily.
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women. No specific geriatric dose adjustments; consider increased risk of thromboembolism and cardiovascular disease in older women.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (DVT, PE, stroke, MI), hypertension, gallbladder disease, impaired liver function, hypertriglyceridemia, glucose intolerance, depression, fluid retention, irregular bleeding, ectopic pregnancy risk.
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, endometrial carcinoma or other estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, known or suspected pregnancy, jaundice with prior pill use, hepatic adenoma or carcinoma.
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No clinically significant food interactions. Grapefruit juice may moderately increase ethinyl estradiol levels; avoid large amounts. Report any known food allergies to excipients.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
FDA Pregnancy Category X. Contraindicated in pregnancy due to known teratogenicity. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects. Second and third trimesters: Associated with fetal adrenal suppression, masculinization of female fetuses (due to progestin component), and potential for other adverse outcomes. Exposure during pregnancy warrants immediate discontinuation.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk in small amounts (progestin: M/P ratio ~0.5; estrogen: minimal). May reduce milk production and affect infant development. Use during lactation is generally not recommended; alternative contraception should be considered.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustment recommended because the drug is contraindicated in pregnancy. Discontinue immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (e.g., increased clearance of steroids) are irrelevant as therapy is terminated.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Norlestrin 28 1/50 (norethindrone 1 mg + ethinyl estradiol 50 mcg) is a high-estrogen-dose combination oral contraceptive. Use for cycle control or contraception; 50 mcg EE raises thromboembolic risk, contraindicated in smokers >35 years, hypertension, migraine with aura, or BMI >30 kg/m². Advise consistent daily timing; missed pills increase breakthrough bleeding and contraceptive failure.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, even during placebo week.,Use backup contraception if you miss more than one active pill.,Do not smoke; risk of blood clots increases, especially over age 35.,Common side effects include nausea, headache, and breast tenderness.,Notify your provider about severe leg pain, chest pain, or vision changes.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORLESTRIN 28 1/50 vs ALYACEN 777, answered by our medical review team.
NORLESTRIN 28 1/50 is a Oral Contraceptive that works by Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release via negative feedback on pituitary, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORLESTRIN 28 1/50 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORLESTRIN 28 1/50 is: One tablet orally once daily, each containing norethindrone 1 mg and ethinyl estradiol 50 mcg.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORLESTRIN 28 1/50 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORLESTRIN 28 1/50 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy due to known teratogenicity. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduc. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.